- Home
- GLMD vs CYCC Comparison
GLMD vs CYCC Comparison
Compare GLMD & CYCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLMD
- CYCC
- Stock Information
- Founded
- GLMD 2000
- CYCC 1992
- Country
- GLMD Israel
- CYCC United States
- Employees
- GLMD N/A
- CYCC N/A
- Industry
- GLMD Biotechnology: Pharmaceutical Preparations
- CYCC Biotechnology: Pharmaceutical Preparations
- Sector
- GLMD Health Care
- CYCC Health Care
- Exchange
- GLMD Nasdaq
- CYCC Nasdaq
- Market Cap
- GLMD 4.5M
- CYCC 3.6M
- IPO Year
- GLMD 2014
- CYCC N/A
- Fundamental
- Price
- GLMD $1.46
- CYCC $0.23
- Analyst Decision
- GLMD
- CYCC Strong Buy
- Analyst Count
- GLMD 0
- CYCC 1
- Target Price
- GLMD N/A
- CYCC $11.00
- AVG Volume (30 Days)
- GLMD 2.6M
- CYCC 161.7K
- Earning Date
- GLMD 05-29-2025
- CYCC 05-13-2025
- Dividend Yield
- GLMD N/A
- CYCC N/A
- EPS Growth
- GLMD N/A
- CYCC N/A
- EPS
- GLMD N/A
- CYCC N/A
- Revenue
- GLMD N/A
- CYCC $43,000.00
- Revenue This Year
- GLMD N/A
- CYCC N/A
- Revenue Next Year
- GLMD N/A
- CYCC $88.68
- P/E Ratio
- GLMD N/A
- CYCC N/A
- Revenue Growth
- GLMD N/A
- CYCC N/A
- 52 Week Low
- GLMD $1.33
- CYCC $0.22
- 52 Week High
- GLMD $23.80
- CYCC $4.00
- Technical
- Relative Strength Index (RSI)
- GLMD 33.38
- CYCC 26.52
- Support Level
- GLMD $1.33
- CYCC $0.22
- Resistance Level
- GLMD $1.55
- CYCC $0.32
- Average True Range (ATR)
- GLMD 0.33
- CYCC 0.02
- MACD
- GLMD -0.04
- CYCC -0.01
- Stochastic Oscillator
- GLMD 5.90
- CYCC 9.09
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.
About CYCC Cyclacel Pharmaceuticals Inc.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.